Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Laura Harvatine

Psychiatry Manassas, VA Medical Doctor

NPI 1669407573 CMS profile 211393

8680 Hospital Way, Manassas, VA 20110

Open in the dashboard

General payments

$1,792

75 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Harvatine of Manassas, VA is reported in the CMS Open Payments database as having received $1,792 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $512 18
2024 General $375 12
2023 General $174 5
2022 General $169 9
2021 General $230 12
2020 General $128 7
2019 General $205 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Harvatine
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Laura Harvatine were reported at $512. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Laura Harvatine Psychiatry median Middle half National median
2019 $205 $184 $59–$605 $163
2020 $128 $119 $36–$372 $114
2021 $230 $143 $43–$576 $132
2022 $169 $153 $50–$590 $149
2023 $174 $170 $56–$651 $160
2024 $375 $179 $57–$673 $164
2025 $512 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $792 27 payments
  2. Otsuka America Pharmaceutical, Inc. $327 15 payments
  3. Alkermes, Inc. $228 13 payments
  4. Teva Pharmaceuticals USA, Inc. $211 10 payments
  5. E.R. Squibb & Sons, L.L.C. $110 4 payments
  6. Lundbeck LLC $88 4 payments
  7. Neurocrine Biosciences, Inc. $36 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,787 74 payments
  2. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $787 26 payments
  2. INVEGA TRINZA $318 9 payments
  3. ABILIFY MAINTENA $231 11 payments
  4. ARISTADA Cns $228 13 payments
  5. ARISTADA Cns $228 13 payments
  6. ARISTADA INITIO $196 12 payments
  7. ARISTADA Cns $156 9 payments
  8. ARISTADA Cns $156 9 payments
  9. ABILIFY ASIMTUFII $152 6 payments
  10. UZEDY $137 6 payments
  11. Other $506 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

572

Median for Psychiatry & Neurology: 100

Drug cost

$684,629

Median for Psychiatry & Neurology: $2,986

Branded share of claims

33.6%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 138 $480,344
Invega Trinza Paliperidone Palmitate Brand 12 $124,108
Abilify Maintena Aripiprazole Brand 22 $62,749
Lurasidone Hcl Generic 25 $5,567
Aripiprazole Generic 20 $3,671
Divalproex Sodium Er Divalproex Sodium Brand 20 $1,965
Haloperidol Decanoate Generic 27 $1,890
Ziprasidone Hcl Generic 15 $1,117
Benztropine Mesylate Generic 64 $639
Haloperidol Generic 24 $534

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $121
$121 138 —
INVEGA TRINZA
  • Janssen Pharmaceuticals, Inc $82
$82 12 —
ABILIFY ASIMTUFII
  • Lundbeck LLC $38
  • Otsuka America Pharmaceutical, Inc. $29
$67 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $52
$52 22 —
ARISTADA
  • Alkermes, Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record